WNT11/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer.
BRCAness
Breast cancer
Metastasis
Network analysis
ROR2
WNT11
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
15 Dec 2021
15 Dec 2021
Historique:
received:
03
06
2021
accepted:
16
11
2021
entrez:
16
12
2021
pubmed:
17
12
2021
medline:
1
3
2022
Statut:
epublish
Résumé
Breast cancer has been associated with activation of the WNT signaling pathway, although no driver mutations in WNT genes have been found yet. Instead, a high expression of the alternative WNT receptor ROR2 was observed, in particular in breast cancer brain metastases. However, its respective ligand and downstream signaling in this context remained unknown. We modulated the expression of ROR2 in human breast cancer cells and characterized their gene and protein expression by RNA-Seq, qRT-PCR, immunoblots and reverse phase protein array (RPPA) combined with network analyses to understand the molecular basis of ROR2 signaling in breast cancer. Using co-immunoprecipitations, we verified the interaction of ROR2 with the identified ligand, WNT11. The functional consequences of WNT11/ROR2 signaling for tumor cell aggressiveness were assessed by microscopy, impedance sensing as well as viability and invasion assays. To evaluate the translational significance of our findings, we performed gene set enrichment, expression and survival analyses on human breast cancer brain metastases. We found ROR2 to be highly expressed in aggressive breast tumors and associated with worse metastasis-free survival. ROR2 overexpression induced a BRCAness-like phenotype in a cell-context specific manner and rendered cells resistant to PARP inhibition. High levels of ROR2 were furthermore associated with defects in cell morphology and cell-cell-contacts leading to increased tumor invasiveness. On a molecular level, ROR2 overexpression upregulated several non-canonical WNT ligands, in particular WNT11. Co-immunoprecipitation confirmed that WNT11 indeed interacts with the cysteine-rich domain of ROR2 and triggers its invasion-promoting signaling via RHO/ROCK. Knockdown of WNT11 reversed the pro-invasive phenotype and the cellular changes in ROR2-overexpressing cells. Taken together, our study revealed a novel auto-stimulatory loop in which ROR2 triggers the expression of its own ligand, WNT11, resulting in enhanced tumor invasion associated with breast cancer metastasis.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer has been associated with activation of the WNT signaling pathway, although no driver mutations in WNT genes have been found yet. Instead, a high expression of the alternative WNT receptor ROR2 was observed, in particular in breast cancer brain metastases. However, its respective ligand and downstream signaling in this context remained unknown.
METHODS
METHODS
We modulated the expression of ROR2 in human breast cancer cells and characterized their gene and protein expression by RNA-Seq, qRT-PCR, immunoblots and reverse phase protein array (RPPA) combined with network analyses to understand the molecular basis of ROR2 signaling in breast cancer. Using co-immunoprecipitations, we verified the interaction of ROR2 with the identified ligand, WNT11. The functional consequences of WNT11/ROR2 signaling for tumor cell aggressiveness were assessed by microscopy, impedance sensing as well as viability and invasion assays. To evaluate the translational significance of our findings, we performed gene set enrichment, expression and survival analyses on human breast cancer brain metastases.
RESULTS
RESULTS
We found ROR2 to be highly expressed in aggressive breast tumors and associated with worse metastasis-free survival. ROR2 overexpression induced a BRCAness-like phenotype in a cell-context specific manner and rendered cells resistant to PARP inhibition. High levels of ROR2 were furthermore associated with defects in cell morphology and cell-cell-contacts leading to increased tumor invasiveness. On a molecular level, ROR2 overexpression upregulated several non-canonical WNT ligands, in particular WNT11. Co-immunoprecipitation confirmed that WNT11 indeed interacts with the cysteine-rich domain of ROR2 and triggers its invasion-promoting signaling via RHO/ROCK. Knockdown of WNT11 reversed the pro-invasive phenotype and the cellular changes in ROR2-overexpressing cells.
CONCLUSIONS
CONCLUSIONS
Taken together, our study revealed a novel auto-stimulatory loop in which ROR2 triggers the expression of its own ligand, WNT11, resulting in enhanced tumor invasion associated with breast cancer metastasis.
Identifiants
pubmed: 34911552
doi: 10.1186/s13046-021-02187-z
pii: 10.1186/s13046-021-02187-z
pmc: PMC8672621
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
395Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 424252458
Organisme : Bundesministerium für Bildung und Forschung
ID : 0316173A
Organisme : Bundesministerium für Bildung und Forschung
ID : 0316173A
Organisme : Bundesministerium für Bildung und Forschung
ID : 0316173A
Organisme : Bundesministerium für Bildung und Forschung
ID : 0316173A
Organisme : Bundesministerium für Bildung und Forschung
ID : 031L0024
Organisme : Bundesministerium für Bildung und Forschung
ID : 031L0024
Informations de copyright
© 2021. The Author(s).
Références
EuPA Open Proteom. 2016 Sep 09;13:1-13
pubmed: 29900117
J Clin Invest. 2016 Feb;126(2):585-98
pubmed: 26690702
PLoS One. 2013 May 21;8(5):e64268
pubmed: 23704984
J Clin Oncol. 2010 Aug 1;28(22):3555-61
pubmed: 20547991
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Biol Chem. 2015 Dec 18;290(51):30562-72
pubmed: 26499793
Sci Rep. 2015 Oct 05;5:14700
pubmed: 26435322
Brief Bioinform. 2008 Jul;9(4):326-32
pubmed: 18436575
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D546-51
pubmed: 16381929
J Cell Biochem. 2020 Oct;121(10):4142-4153
pubmed: 32048761
Tumour Biol. 2016 Oct;37(10):13049-13057
pubmed: 27514543
J Ultrastruct Res. 1965 Feb;12:187-206
pubmed: 14289427
Biotechniques. 2014 Sep 01;57(3):125-35
pubmed: 25209047
Carcinogenesis. 2011 Mar;32(3):434-42
pubmed: 21173432
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
BMC Cancer. 2013 Apr 02;13:174
pubmed: 23547709
Cells. 2021 Jan 12;10(1):
pubmed: 33445713
Bioinformatics. 2019 Jun 1;35(12):2084-2092
pubmed: 30395178
Front Genet. 2016 Apr 05;7:42
pubmed: 27092172
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
J Cancer Res Clin Oncol. 2015 Feb;141(2):243-54
pubmed: 25209439
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Oncogene. 2006 Apr 6;25(15):2273-84
pubmed: 16288205
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807717
Cell. 2001 Dec 28;107(7):843-54
pubmed: 11779461
J Biol Chem. 2020 May 1;295(18):5995-6006
pubmed: 32193207
J Clin Invest. 2020 Aug 3;130(8):4252-4265
pubmed: 32657779
Nat Rev Mol Cell Biol. 2012 Dec;13(12):767-79
pubmed: 23151663
Development. 2002 Nov;129(22):5227-39
pubmed: 12399314
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
J Biol Chem. 2014 Jul 25;289(30):20664-76
pubmed: 24928507
Bioinformatics. 2015 Nov 15;31(22):3718-20
pubmed: 26209431
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Front Oncol. 2017 Jun 26;7:135
pubmed: 28695110
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Clin Exp Metastasis. 2016 Apr;33(4):309-23
pubmed: 26862065
Genes Dev. 2003 Jan 15;17(2):295-309
pubmed: 12533515
BMC Bioinformatics. 2006 Sep 06;7 Suppl 2:S13
pubmed: 17118134
Acta Biochim Biophys Sin (Shanghai). 2011 Oct;43(10):745-56
pubmed: 21903638
PLoS One. 2015 Dec 03;10(12):e0144014
pubmed: 26632845
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Dev Biol. 2003 Dec 15;264(2):376-90
pubmed: 14651925
J Biol Chem. 2014 Jun 27;289(26):18122-36
pubmed: 24841207
Aging (Albany NY). 2020 Jul 2;12(13):13115-13127
pubmed: 32614787
Cell Commun Signal. 2019 Aug 28;17(1):109
pubmed: 31462314
Oncogene. 2017 Oct 26;36(43):5958-5968
pubmed: 28650466
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490
Sci Rep. 2018 May 9;8(1):7329
pubmed: 29743726
Genes Dev. 2010 Nov 15;24(22):2517-30
pubmed: 21078818